Proteomedix and Dynex® Technologies enter into strategic alliance to provide automated workflows for Proclarix®
Schlieren-Zurich, CH and Chantilly, VA, USA, May 12, 2020. Proteomedix, the Swiss cancer diagnostics company and Dynex Technologies, announce today a strategic partnership enabling Proteomedix to establish automated workflows for their prostate cancer diagnostics test and sell Dynex instruments to the global clinical market. The partnership builds on the longstanding relationship between both companies with Dynex Technologies’ industry proven automated ELISA instrumentation and Proteomedix’ Proclarix for prostate cancer diagnosis.
Dynex’s range of automation systems offers perfect solutions for Proteomedix’ customers. With an instrument base of over 7,500 systems globally, Dynex has a proven track record of quality, acceptance and success in developing instruments for automating clinical assays. Designed with automated clinical laboratory workflows in mind, Proclarix was clinically validated on the Dynex DSX® platform. Protocols for the DS2®, and Agility® platforms will be made available in the near future.
“Proteomedix and Dynex have worked together for a number of years during the development and clinical validation phase of Proclarix®. Now that we are directly selling and supporting Proclarix in conjunction with the Dynex automation systems, Proteomedix is well positioned to offer laboratory customers a single point of contact, full solution for their automated testing needs, improving the installation, training and implementation process. With multiple instrument offerings customers can choose a “right-sized” instrument that fits their needs.” said Helge Lubenow, CEO of Proteomedix.
“Partnering with Proteomedix aligns with our initiatives to drive growth of our core product line by leveraging partnerships to offer a growing menu of applications in the specialty oncology space” remarked David Sholehvar, MD, CEO of Dynex Technologies. “Proteomedix has a very exciting product offering and pipeline. Our mutual commitment to excellence will most certainly drive value for our customers."
About Proclarix®
Proclarix® is CE marked, intended for in vitro diagnostic use and indicated for prostate cancer diagnosis in patients with normal digital rectal exam (DRE), enlarged prostate volume and elevated levels of PSA at 2-10 ng/ml. Proclarix is a risk score combining in-vitro assays for the quantitative detection of biomarkers with a proprietary algorithm to assess a patient`s risk of having clinically significant prostate cancer. Detection of prostate cancer-related biomarkers in blood serum using the Proclarix risk score has been demonstrated in multiple clinical studies to be a reliable indicator of the presence of clinically significant prostate cancer. Proclarix is currently not available in the United States of America.
About Proteomedix
Proteomedix is a healthcare company whose mission is to transform prostate cancer diagnosis. The company has identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis and therapy management. The lead product Proclarix® is a blood based prostate cancer test panel and risk score introduced to the market early 2020. Proteomedix is located in the Bio-Technopark of Schlieren, Switzerland. For more information, visit www.proteomedix.com.
About Dynex Technologies
DYNEX Technologies, Inc. is an original pioneer and market leader in automated microplate technology. With 20 years of experience in ELISA automation, DYNEX provides laboratories all over the world with the flexibility to automate assays of their choice with true walk away capabilities. Our instruments are offered through a global network of first class distributors resulting in thousands of placements that meet the rigorous demands of the most challenging applications, while improving laboratory efficiency and ultimately helping improve health outcomes.
For further details, please contact:
Christian Brühlmann, CBO
bruehlman@proteomedix.com
Duane Steele, VP Sales and Marketing
Proclarix@dynex.com